编者按：第46届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2023年12月5日至9日在美国得克萨斯州圣安东尼奥举行，SABCS作为乳腺癌领域规模最大，最具影响力的国际性会议，届时多项重磅研究结果将在会上公布。本文将乳腺癌领域值得关注的重磅研究进行了汇总，以飨读者。
Late Breaking Abstracts Oral Session
专场：Late Breaking Abstracts Oral Session
时间：12月8日12:00 pm-12:45 pm
地点：Star at Night Ballroom 1-2
主持人：Evanthia Roussos Torres
摘要：LBO1-01 Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer:Updated event-free survival results from the phase 3 KEYNOTE-522 study
3期KEYNOTE-522研究的无事件生存期（EFS）数据更新：新辅助帕博利珠单抗或安慰剂+化疗后辅助帕博利珠单抗或安慰剂治疗早期TNBC
讲者：Peter Schmid，Centre for Experimental Cancer Medicine，Barts Cancer Institute，Queen Mary University London，London，United Kingdom
摘要：LBO1-02 Pathologic complete response(pCR)of neoadjuvant therapy with or without atezolizumab in HER2-positive，early high-risk and locally advanced breast cancer:APTneo Michelangelo randomized trial
APTneo Michelangelo研究：用或不用阿替利珠单抗新辅助治疗HER2+早期高危和局晚期乳腺癌病理完全缓解（pCR）的疗效
讲者：Luca Gianni，Fondazione Michelangelo，Milan，Italy
摘要：LBO1-03 Randomized Phase II Study of Neoadjuvant Nivolumab(N)2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel(CbP)vs concurrent N+CbP in Triple Negative Breast Cancer(TNBC):(BCT1902/IBCSG 61-20 Neo-N)
Ⅱ期随机BCT1902/IBCSG 61-20 Neo-N研究：新辅助纳武利尤单抗（N）单药治疗（2周）后接受N+卡铂+紫杉醇（CbP）（12周）vs同时接受N+CbP治疗TNBC
讲者：Nicholas Zdenkowski，Breast Cancer Trials，Newcastle，NSW，Australia
摘要：LBO1-04 Primary results from a phase 2a study of zanidatamab(zani)+palbociclib(palbo)+fulvestrant(fulv)in HER2+/HR+metastatic breast cancer(mBC)
Zanidatamab（zani）+哌柏西利+氟维司群治疗HER2+/HR+转移性乳腺癌（mBC）的2a期研究的主要结果
讲者：Santiago Escrivá-de-Romani，Vall d’Hebron Institute of Oncology(VHIO)，Vall d’Hebron University Hospital，Barcelona，Spain
摘要：LBO1-05 Impact of age and ovarian function suppression(OFS)on endocrine response to short preoperative endocrine therapy(ET):Results from the multicenter ADAPTcycle trial(n=4，334)
年龄和卵巢功能抑制（OFS）对短术前内分泌治疗反应的影响：来自多中心ADAPTcycle试验的结果（n=4334）
讲者：Oleg Gluz，West German Study Group，Moenchengladbach，Germany;Breast Center Niederrhein，Ev.Hospital Bethesda，Moenchengladbach，Germany
General Sessions
专场：GENERAL SESSION 1
时间：12月6日9:00 am-12:00 pm
地点：Hall 1
主持人：Allison W.Kurian
摘要：GS01-01 Biomarker results in high-risk estrogen receptor positive，human epidermal growth factor receptor 2 negative primary breast cancer following neoadjuvant chemotherapy±nivolumab:An exploratory analysis of CheckMate 7FL
新辅助化疗±纳武利尤单抗治疗高危ER+/HER2-原发性乳腺癌的生物标志物结果：CheckMate 7FL的探索性分析
讲者：Sherene Loi，Peter McCallum Cancer Centre，Melbourne，Australia
摘要：GS01-02 Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy，followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2−breast cancer:KEYNOTE-756
新辅助帕博利珠单抗或安慰剂+化疗，序贯辅助帕博利珠单抗或安慰剂+内分泌治疗早期高危ER+/HER2-乳腺癌的3期研究：KEYNOTE-756
讲者：Joyce O’Shaughnessy，Baylor University Medical Center，Dallas，Texas
摘要：GS01-03 Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy:interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial.
在Ⅱ期和Ⅲ期三阴性乳腺癌的辅助化疗中加入阿替利珠单抗不太可能提高疗效：ALEXANDRA/IMpassion030 3期试验的中期分析。
讲者：Michail Ignatiadis，Institut Jules Bordet，UniversitéLibre de Bruxelles，Bruxelles，Belgium
摘要：GS01-05 Pembrolizumab+olaparib vs pembrolizumab+chemotherapy after induction with pembrolizumab+chemotherapy for locally recurrent inoperable or metastatic TNBC:Randomized open-label phase 2 KEYLYNK-009 study
在帕博利珠单抗+化疗诱导后对比帕博利珠单抗+奥拉帕利和帕博利珠单抗+化疗治疗局部复发性不可手术或转移性TNBC：随机开放标签的2期KEYLYNK-009研究
讲者：Hope S.Rugo，University of California San Francisco Helen Diller Family Comprehensive Cancer Center，San Francisco，California
摘要：GS01-06 Advancing evidence of the associations between specific benign breast diagnoses and future breast cancer risk
进一步证明特定良性乳腺诊断与未来乳腺癌风险之间的关联
讲者：Olivia Sattayapiwat，University of California at Davis，Davis，California
摘要：GS01-08 CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+breast cancer
CDK4/6抑制在NF1缺失的ER+乳腺癌中潜在易感
讲者：Eric Chang，Lester Sue Smith Breast Center，Baylor College of Medicine，Houston，Texas
摘要：GS01-10 HER2CLIMB-02:Randomized，double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer
HER2CLIMB-02：图卡替尼+T-DM1治疗先前经治的HER2阳性转移性乳腺癌，随机双盲的3期试验
讲者：Sara Hurvitz，Fred Hutchinson Cancer Center/University of Washington，Seattle，Washington
专场：General Session 2
时间：12月7日8:15 am-11:15 am
地点：Hall 1
主持人：Antoinette R.Tan
摘要：GS02-01 Randomised phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive，HER2-breast cancer:efficacy，safety and biomarker results from TROPION-Breast01.
datopotamab deruxtecan对比化疗治疗不能手术或转移性HR+/HER2-乳腺癌患者的随机3期研究：TROPION-Breast01的疗效、安全性和生物标志物结果
讲者：Aditya Bardia，Massachusetts General Hospital Cancer Center，Boston，Massachusetts
摘要：GS02-02 Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection?The OPBC05/EUBREAST-14R/ICARO study
OPBC05/EUBREAST-14R/ICARO研究：新辅助化疗后的淋巴结孤立肿瘤细胞（ITCs）是腋窝清扫的指征吗？
讲者：Giacomo Montagna，Memorial Sloan Kettering Cancer Center，New York，New York
摘要：GS02-04 Surgical treatment of women with breast cancer and a BRCA1 mutation:an international analysis of the impact of bilateral mastectomy on survival
BRCA1突变女性乳腺癌的手术治疗：双侧乳房切除对生存影响的国际分析
讲者：Kelly Metcalfe，University of Toronto，Toronto，Ontario，Canada
摘要：GS02-05 Overview of axillary treatment in early breast cancer:patient-level meta-analysis of long-term outcomes among 20，273 women in 29 randomised trials
早期乳腺癌腋窝治疗综述：对29项随机试验中20273名女性长期结局的患者水平荟萃分析
讲者：Gurdeep S.Mannu，University of Oxford，Oxford，England
摘要：GS02-06 Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection–first results from the international randomized SENOMAC trial.
未完成腋窝淋巴结清扫的前哨淋巴结阳性乳腺癌患者的无复发生存期——国际随机SENOMAC试验的首个结果
讲者：Jana de Boniface，Karolinska Institutet，Stockholm，Sweden;Capio St.Göran’s Hospital，Stockholm，Sweden
摘要：GS02-07 Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy:primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304
NRG Oncology/NSABP B-51/RTOG 1304的主要结局：局部区域放射治疗在新辅助化疗后病理淋巴结阴性的活检证实腋窝淋巴结受累者
讲者：Eleftherios Mamounas，Orlando Health Cancer Institute，Orlando，Florida
GS02-08 Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer
IDEA研究5年结果：绝经后50-69岁基因组筛选有利的Ⅰ期乳腺癌患者，在保乳手术后无放疗的内分泌治疗效果
讲者：Reshma Jagsi，Emory University，Atlanta，Georgia
摘要：GS02-10 Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer:the multinational randomized controlled PREFERABLE-EFFECT study
结构化和个性化运动计划对转移性乳腺癌患者疲劳和健康相关生活质量的影响：PREFERABLE-EFFECT study多国随机对照研究
讲者：Anne M.May，University Medical Center，Utrecht，Netherlands
摘要：GS02-11 Fertility preservation and assisted reproductive technologies(ART)in breast cancer(BC)patients(pts)interrupting endocrine therapy(ET)to attempt pregnancy
乳腺癌患者中断内分泌治疗（ET）试图怀孕的生育能力保存和辅助生殖技术（ART）
讲者：Hatem A.Azim，Jr.，Monterrey Institute of Technology，Monterrey，Mexico
摘要：GS02-13 Pregnancy after breast cancer in young women with germline BRCA pathogenic variants:results from an international cohort study
一项国际队列研究的结果：胚系BRCA致病变异的年轻女性患乳腺癌怀孕的治疗
讲者：Matteo Lambertini，University of Genova-San Martino Hospital，Genova，Italy
专场：General Session 3
时间：12月8日8:15 am-11:15 am
地点：Hall 1
主持人：Mothaffar F.Rimawi
摘要：GS03-01 Magnetic Resonance Imaging and a 12-gene expression assay to optimize local therapy for ductal carcinoma in situ:5-year clinical outcomes of E4112
磁共振成像和12基因表达测定以优化乳腺导管原位癌局部治疗：E4112研究5年临床结果
讲者：Seema Khan，Northwestern University，Evanston，Illinois
摘要：GS03-02 Mammographic surveillance in early breast cancer patients aged 50 years or over:results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography
Mammo-50非劣效性试验：≥50岁早期乳腺癌患者进行乳腺X线摄影监测，对比每年一次与低频率乳腺X线摄影监测的结果
讲者：Janet A.Dunn，University of Warwick，Coventry，England
摘要：GS03-03 Ribociclib(RIB)+nonsteroidal aromatase inhibitor(NSAI)as adjuvant treatment in patients with HR+/HER2−early breast cancer:final invasive disease–free survival(iDFS)analysis from the NATALEE trial
瑞波西利+非甾体芳香酶抑制剂（NSAI）作为HR+/HER2-早期乳腺癌患者的辅助治疗：来自NATALEE试验的最终侵袭性无病生存期（iDFS）分析
讲者：Gabriel N.Hortobagyi，The University of Texas MD Anderson Cancer Center，Houston，Texas
摘要：GS03-04 Novel mechanisms of CDH1 inactivation in breast invasive lobular carcinoma unveiled by the integration of artificial intelligence and genomics
人工智能与基因组学结合揭示乳腺浸润性小叶癌中CDH1失活的新机制
讲者：Fresia Pareja，Pathology，Memorial Sloan Kettering Cancer Center，New York，New York
摘要：GS03-06 Genomic and transcriptomic profiling of primary tumors from patients with HR+，HER2-，node-positive，high-risk early breast cancer in the monarchE trial
monarchE研究中HR+，HER2-，淋巴结阳性，高危早期乳腺癌患者原发肿瘤的基因组和转录组学分析
讲者：Nicholas C.Turner，Royal Marsden Hospital，Institute of Cancer Research，London，United Kingdom
摘要：GS03-07 Protocol-defined biomarker analysis in the PALLAS(AFT-05)adjuvant trial:Genomic subtype derived from RNA sequencing of HR+/HER2-early breast cancer
在PALLAS（AFT-05）辅助试验中，方案定义的生物标志物分析：来自HR+/HER2-早期乳腺癌的RNA测序的基因组亚型
讲者：Daniel Stover，Ohio State University Comprehensive Cancer Center，Columbus，Ohio
摘要：GS03-09 Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers
转移性乳腺癌中融合RNA的特性和治疗利用
讲者：Nolan Priedigkeit，Dana-Farber Cancer Institute/Broad Institute of MIT and Harvard，Boston，Massachusetts
摘要：GS03-10 Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations
PI3K-α变构抑制克服继发性PIK3CA突变介导的对正构抑制剂的靶点依赖性耐药
讲者：Andreas Varkaris，Massachusetts General Hospital，Boston，Massachusetts
摘要：GS03-11 Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity
胚系介导的免疫编辑塑造乳腺癌亚型和转移倾向
讲者：Christina Curtis，Stanford University，Stanford，California
摘要：GS03-12 Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy:KATHERINE final IDFS and updated OS analysis
KATHERINE最终IDFS和更新的OS结果分析：新辅助化疗和HER2靶向治疗后残余侵袭性早期乳腺癌的辅助用T-DM1对比曲妥珠单抗的Ⅲ期研究
讲者：Sibylle Loibl，German Breast Group，Neu-Isenburg，Germany;Centre for Haematology and Oncology Bethanien，Frankfurt，Germany
Rapid-fire Mini-Oral Sessions
专场：Rapid Fire Session 1
时间：12月6日12:15-1:00PM
地点：Hall 1
主持人：Carlos L.Arteaga
摘要：RF01-01 SERENA-3 A randomized pre-surgical window of opportunity study assessing dose and duration of camizestrant treatment in post-menopausal women with ER-positive，HER2-negative primary breast cancer
一项随机的术前机会窗研究，评估绝经后ER阳性、HER2-原发性乳腺癌患者camizestrant治疗的剂量和持续时间
讲者：John Robertson，University of Nottingham，Nottingham，United Kingdom;University Hospitals of Derby and Burton，Derby，United Kingdom
摘要：RF01-02 A randomized Phase I pre-operative window trial of transdermal endoxifen in women planning mastectomy:evaluation of dermal safety，intra-mammary drug distribution，and biologic effects
一项Ⅰ期随机手术前窗口试验：他莫昔芬经皮内用于计划乳房切除术的女性，对其皮肤安全性、乳腺内药物分布和生物效应的评估
讲者：Oukseub Lee，Northwestern University，Chicago，Illinois
摘要：RF01-03 PARSIFAL-LONG:Extended follow-up of hormone receptor-positive/HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs.letrozole and palbociclib in the PARSIFAL study
PARSIFAL-LONG：PARSIFAL研究中，接受氟维司群+哌柏西利vs来曲唑+哌柏西利的ER+/HER2-晚期乳腺癌患者的延长随访
讲者：Antonio Llombart-Cussac，Hospital Arnau de Vilanova，Valencia，Spain
摘要：RF01-04 Final results from the phase 2，open-label FOENIX-MBC2 study:efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2−breast cancer harboring high-level FGFR1 gene amplification
2期开放标签FOENIX-MBC2研究的最终结果：futibatinib治疗伴有高水平FGFR1基因扩增的局部晚期/转移性HR+/HER2-乳腺癌成年患者的有效性和安全性
讲者：Senthil Damodaran，The University of Texas MD Anderson Cancer Center，Houston，Texas
摘要：RF01-05 Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer
PARP抑制剂耐药的BRCA1/2突变乳腺癌中RAD51 foci和复制叉动力学的功能评估
讲者：Elizabeth Harvey-Jones，King’s College London Great，Maze Pond，United Kingdom
摘要：RF01-06 Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer:a multicenter phase II trial based on a Bayesian adaptive randomized design
toripalimab联合节律化疗治疗HER2-转移性乳腺癌的疗效和安全性：一项基于贝叶斯自适应随机设计的多中心Ⅱ期试验
讲者：莫红楠（中国医学科学院肿瘤医院）
摘要：RF01-07 The efficacy and safety of tinengotinib in patients with advanced or metastatic HR+/HER2-breast cancer or TNBC
tinengotinib治疗晚期或转移性HR+/HER2-乳腺癌或TNBC的疗效和安全性
讲者：Piha-Paul Sarina，The University of Texas MD Anderson Cancer Center Houston，Texas
摘要：RF01-08 A randomized，open-label phase III trial evaluating low-dose vs standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in solid tumors(OLAnzaPiNE)
一项随机、开放标签的Ⅲ期试验，评估低剂量奥氮平与标准剂量奥氮平联合三联止吐治疗预防实体瘤患者高度致吐性化疗引起的恶心和呕吐（OLAnzaPiNE）
讲者：Jyoti Bajpai，Tata Memorial Centre，Homi Bhabha National Institute(HBNI)，Mumbai，India
专场：Rapid Fire Session 2
时间：12月7日12:00 pm-12:45 pm
地点：Hall 1
主持人：Virginia Kaklamani
摘要：RF02-01 A multicenter，phase i/ii trial of anastrozole，palbociclib，trastuzumab，and pertuzumab in hormone receptor(hr)-positive，HER2-positive metastatic breast cancer(ASPIRE)
阿那曲唑、哌柏西利、曲妥珠单抗+帕妥珠单抗治疗HR+/HER2+转移性乳腺癌（ASPIRE）的多中心Ⅰ/Ⅱ期临床试验
讲者：Amy Tiersten，Icahn School of Medicine at Mount Sinai，Tisch Cancer Institute，New York，New York
摘要：RF02-02 BBO-10203，a first-in-class，orally bioavailable，selective covalent small molecule that inhibits RAS-driven PI3Kαactivity without affecting glucose metabolism
BBO-10203，一种首创的口服生物可利用的选择性共价小分子，在不影响葡萄糖代谢的情况下可抑制RAS驱动的PI3Kα活性
讲者：Pedro Beltran，BridgeBio Pharma Oncology Therapeutics，Orinda，California
摘要：RF02-03 Trastuzumab deruxtecan(T-DXd)in combination with anastrozole or fulvestrant in patients with HER2-low HR+advanced/metastatic breast cancer:a Phase 1b，open-label，multicenter，dose-expansion study(DESTINY-Breast08)
T-DXd联合阿那曲唑或氟维司群治疗HER2低表达、HR+晚期/转移性癌症患者：一项1b期、开放标签、多中心、剂量扩大研究（DESTINY-Breast08研究）
讲者：Komal Jhaveri，Memorial Sloan Kettering Cancer Center，New York，New York
摘要：RF02-04 A phase III study comparing trastuzumab emtansine with trastuzumab，pertuzumab，and docetaxel in older patients with metastatic HER2-positive breast cancer(JCOG1607 HERB TEA study)
一项比较恩美曲妥珠单抗与曲妥珠单抗、帕妥珠单抗和多西他赛治疗转移性HER2阳性乳腺癌老年患者的Ⅲ期研究（JCOG1607 HERB TEA研究）
讲者：Akihiko Shimomura，National Center for Global Health and Medicine，Tokyo，Japan
摘要：RF02-05 Report on cohort expansion of phase i study to investigate the safety，tolerability，pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2 low breast cancer
探索BB-1701在局部晚期/转移性HER2低表达乳腺癌患者中的安全性、耐受性、药代动力学和抗肿瘤活性的Ⅰ期研究队列扩展报告
作者：Pamela Munster，University of California San Francisco，San Francisco，California
摘要：RF02-06 AVIATOR/TBCRC045:A randomized phase II study of vinorelbine(N)+trastuzumab(H)alone or combined with avelumab(A)+/-utomilumab(U)in patients(pts)with HER2+metastatic breast cancer(MBC)(NCT03414658)
AVIATOR/TBCRC045：长春瑞滨（N）+曲妥珠单抗（H）联合或不联合阿维鲁单抗±utomilumab治疗HER2+转移性乳腺癌患者的随机Ⅱ期研究（NCT03414658）
讲者：Adrienne Waks，Dana-Farber Cancer Institute，Boston，Massachusetts
摘要：RF02-07 Precocious modulation of metabolic and immunological parameters predicts tumor response to fasting-mimicking diet plus chemotherapy in patients with early stage TNBC
代谢和免疫参数的提前调节预测了早期TNBC患者对模拟禁食饮食加化疗的肿瘤反应
讲者：Claudio Vernieri，Fondazione IRCCS Istituto Nazionale dei Tumori，Milan，Italy
Poster Spotlights
PS02-02 Patient-reported outcomes from the Phase 3 CAPItello-291 trial investigating capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer
Capivasertib+fulvestrant治疗芳香化酶抑制剂耐药的HR阳性/HER2-晚期乳腺癌患者的3期CAPItello-291试验的PRO结果
报告时间：12月5日5:30 pm-6:30 pm
地点：Stars at Night Ballroom 1-2
讲者：Hope S.Rugo（University of California San Francisco Helen Diller Family Comprehensive Cancer Center，San Francisco，California）
京公网安备 11010502033352号